Entest Biomedical, Inc. announced that the company's recent research study conducted on ImenVax(TM) (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax(TM) appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation.